8-K: Turn Therapeutics Expands Atopic Dermatitis Trial, Appoints Ex-FDA Chief

Turn Therapeutics announced positive interim Phase 2 data for GX-03 in atopic dermatitis, leading to an expanded trial population, and appointed former FDA Commissioner Dr. Stephen Hahn to a key role.

Summary

• Turn Therapeutics reported on its second quarter of 2026, highlighting progress in its GX-03 Phase 2 study for atopic dermatitis.
• Interim data suggests GX-03 shows efficacy in a broader patient population, including those with moderate-to-severe lesions but lower overall disease extent.
• The company is expanding the Phase 2 study to enroll approximately 120-135 patients.
• Dr. Stephen M. Hahn, former FDA Commissioner, has been appointed as Executive Clinical and Regulatory Lead.
• First peer-reviewed preclinical data published in the Journal of Dermatological Treatment shows GX-03 significantly reduced skin inflammation.
• Turn Therapeutics plans to expand GX-03 development into hidradenitis suppurativa (HS), targeting first patient dosing in Q2 2027.
• The company had $10.3 million in cash and cash equivalents as of June 30, 2026, providing an estimated operational runway into Q3 2027.
• General and administrative expenses decreased slightly to $1.2 million for Q2 2026 compared to $1.3 million in Q2 2025.
• Research and development expenses increased to $0.5 million for Q2 2026 from $0.1 million in Q2 2025, due to increased trial activity.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, with encouraging interim data and strategic appointments bolstering the company's outlook.

Positives

• Encouraging interim Phase 2 data for GX-03 in atopic dermatitis, showing treatment separation across key efficacy endpoints.
• Expansion of the Phase 2 study to include a broader patient population with moderate-to-severe lesions but lower overall disease extent, addressing an underserved market.
• Appointment of Dr. Stephen M. Hahn, former FDA Commissioner, to a leadership role, strengthening clinical and regulatory expertise.
• Publication of the first peer-reviewed preclinical study demonstrating GX-03's anti-inflammatory activity.
• Confirmation of on-track Phase 2 enrollment completion by the end of 2026.
• Favorable safety profile observed in Stage 1 of the Phase 2 study with no serious adverse events or discontinuations due to adverse events.
• Strategic expansion of GX-03 development into hidradenitis suppurativa (HS), targeting a significant unmet need.
• Sufficient cash reserves ($10.3 million) providing an estimated operational runway into the third quarter of 2027.

Negatives

• Significant net loss of $5.85 million for the three months ended June 30, 2026, compared to a net loss of $1.24 million for the same period in 2025.
• Net loss per common share of $(0.20) for the three months ended June 30, 2026.
• Substantial increase in R&D expenses to $0.5 million for Q2 2026 from $0.1 million in Q2 2025, indicating higher operational costs.
• Total liabilities increased significantly to $16.3 million as of June 30, 2026, from $7.5 million as of December 31, 2025.
• Stockholders equity decreased substantially to $0.7 million as of June 30, 2026, from $4.7 million as of December 31, 2025.

Risks

• The success of development programs is subject to inherent uncertainties and risks.
• Availability of additional financing may be a challenge.
• Turn Therapeutics' ability to execute its strategic plan is subject to risks.
• Forward-looking statements are based on assumptions about future events that may not prove accurate.
• Risks related to the business of Turn Therapeutics in general, as disclosed in SEC filings.

Future Outlook

The company expects to complete enrollment for its Phase 2 atopic dermatitis study by the end of 2026 and plans to initiate a Phase 2a study for hidradenitis suppurativa in the second quarter of 2027. Current cash reserves are projected to fund operations into the third quarter of 2027.

Management Comments

• "The second quarter was one of the most productive periods in Turn Therapeutics history."
• "Our review of interim GX-03 Phase 2 data showed activity across a broader range of atopic dermatitis patients than anticipated, including patients with moderate-to-severe lesions despite lower EASI, or Eczema Area and Severity Index."
• "This represents an important and underserved population that may need stronger treatment options but can be ineligible for certain advanced therapies because their disease does not affect enough of the body."
• "These findings allowed us to refine Stage 2 around this broader population and the endpoints showing the most encouraging treatment separation."
• "During the quarter, we also appointed Dr. Stephen Hahn to strengthen our clinical and regulatory leadership, published our first peer-reviewed preclinical data demonstrating GX-03s anti-inflammatory activity, and advanced our FDA Type B meeting package."
• "The Phase 2 study continued uninterrupted, and we remain on track to complete enrollment by year-end."

Industry Context

StockSavvy.ai notes that Turn Therapeutics is operating in the competitive dermatology space, focusing on targeted, non-systemic therapies. The expansion of their Phase 2 trial to include patients with moderate-to-severe lesions but lower overall disease extent addresses a specific unmet need, potentially differentiating GX-03 from broader-acting treatments. The planned expansion into hidradenitis suppurativa also aligns with the industry trend of seeking novel treatments for chronic inflammatory skin conditions.

Comparison to Industry Standards

• The interim efficacy data for GX-03 in atopic dermatitis shows promising treatment separation compared to vehicle across multiple endpoints: 61.5% vs 8.3% achieved clear/almost clear skin at Week 4; 69.2% vs 25.0% achieved at least 75% EASI improvement at Week 4; 53.8% vs 16.7% achieved at least 90% EASI improvement at Week 8; and 46.2% vs 8.3% achieved complete EASI clearance at Week 8. These results will be compared against benchmarks from other topical and systemic therapies for atopic dermatitis once further data is available.
• The planned Phase 2a study in hidradenitis suppurativa will utilize established measures of HS improvement and patient-reported outcomes, allowing for comparison with existing treatments for HS, such as biologics and other anti-inflammatory agents.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact expected from promising clinical data and strategic appointments, potentially leading to increased investor confidence. However, continued net losses and increased R&D spending may require future financing.
• Patients: Potential for new, effective treatment options for atopic dermatitis and hidradenitis suppurativa, particularly for those with moderate-to-severe lesions not adequately served by current therapies.
• Employees: Continued development and expansion of clinical programs may lead to growth and new opportunities within the company.

Next Steps

• Complete enrollment for the Phase 2 study of GX-03 in atopic dermatitis by the end of 2026.
• Expand Stage 2 of the Phase 2 study to enroll approximately 120 to 135 patients.
• Plan and initiate a Phase 2a study of GX-03 in hidradenitis suppurativa, targeting first patient dosing in Q2 2027.
• Continue to advance FDA Type B meeting package discussions.
• Publish additional scientific data on GX-03's potential mechanism of action.

Key Dates

Recommendation

The company shows promising clinical development with positive interim data and strategic hires, but significant net losses and increased R&D expenses warrant a cautious 'hold' rating. The cash runway is adequate for now, but future financing needs and the success of late-stage trials remain key factors.

Keywords

Atopic Dermatitis, GX-03, Hidradenitis Suppurativa, Clinical Trial, Biotechnology, Inflammatory Skin Disease, Phase 2 Study, Drug Development